Abstract
Objectives Conventional lung biopsy for critically ill patients who under invasive mechanical ventilation (IMV) is limited due to high risks of procedure-related complications. We developed a novel technique named bronchus-blocked ultrasound-guided percutaneous transthoracic needle biopsy (BUS-PTNB) to mitigate the risks of biopsy under IMV, but its safety and efficacy have not been prospectively evaluated.
Methods In this prospective, single-arm trial (Chictr.org, ChiCTR2100054047), invasively ventilated patients with undiagnosed lung opacities were screened and underwent BUS-PTNB after enrollment. The peri-operative conditions, severity of complications, pathological findings, and tissue-based metagenomic next-generation sequencing (mNGS) results were systemically evaluated.
Results A total of 22 critically ill patients (18 men, mean age, 64.2 years [SD 11.7], APACHE II score, 27.0 [SD 5.6], PaO2/FiO2 ratio, 120.5 [IQR 91.9–169.1]) under IMV were enrolled in the study. Throughout the procedure, there were no significant changes in respiratory rate or PaO2. Biopsy-related complications occurred in 3 patients (13.6%), including pneumothorax (n=1, 4.5%), intrabronchial hemorrhage (n=2, 9.1%), and hemothorax (n=3, 13.6%). Notably, one patient (P10) required a blood transfusion due to hemothorax, which was classified as a severe complication (1/22, 4.5%). Satisfactory biopsy samples were obtained from 21 patients (95.5%) for pathological study and from all 22 patients (100%) for mNGS.
Conclusions The novel BUS-PTNB is a promising bedside biopsy technique for ICU patients under IMV with acceptable complication risk. This technique may prove instrumental in advancing pathological studies of severe lung diseases.
Question We developed bronchus-blocked ultrasound-guided percutaneous transthoracic needle biopsy (BUS-PTNB) for patients under invasive mechanical ventilation, but its safety and efficacy have not been prospectively evaluated.
Findings Patients’ vital signs showed no significant fluctuations. Biopsy-related complications occurred in 3 patients out of 22. Satisfactory samples were obtained for pathological study and mNGS.
Clinical Relevance BUS-PTNB is a promising bedside biopsy technique for ICU patients under IMV with acceptable complication risk. This technique may prove instrumental in advancing pathological studies of severe lung diseases.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2100054047
Funding Statement
The study was funded by 135 Project for Disciplines of Excellence, Clinical Research Incubation; 135 Project for Disciplines of Excellence, West China Hospital, Sichuan University (grant No. 2022HXFH005, ZYJC21032).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of West China Hospital gave ethical approval for this work. The trial protocol was approved by the West China Hospital Ethics Board (approval # 2021-1250) on 2021.11.19 and registered with the Chinese Clinical Trial Registry (registration # ChiCTR2100054047) on 2021.12.07.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
